Takeda’s TAK-881 SCIG Product Meets Primary and Secondary Endpoints in Phase II/III Clinical Trial
Takeda’s pivotal Phase II/III clinical trial of its investigational TAK-881K SCIG 20% with recombinant human hyaluronidase) in patients with primary immunodeficiency met its primary and secondary endpoints.
FDA Approves Expanded Label for ASCENIV for PI Patients 2 Years and Older
The U.S. Food and Drug Administration has approved ADMA Biologics’ supplemental biologics license application to expand the prescribing information to primary humoral immunodeficiency indication to pediatric patients 2 years of age and older.
New Bill Introduced to Ensure Dedicated Payment for IVIG in Skilled Nursing Facilities
U.S. Representatives Adrian Smith (R-NE-03) and Doris Matsui (D-CA-07) have introduced the PI Post Acute Access Act to expand access to lifesaving care for individuals with primary immunodeficiencies
IVIG Results in Improved Response Rate in Patients with Autoimmune Encephalitis
Intravenous immune globulin (IVIG) improved clinical response rates in patients with autoimmune encephalitis (AE) who had inadequate response to steroid pulse therapy.
Researchers Awarded $900,000 Grant to Develop Drug to Fight Cancer
Wei Gao, PhD, assistant professor of pharmacology at the University of Houston College of Pharmacy, has received a $900,000 grant from the Cancer Prevention and Research Institute of Texas to develop a stronger and more targeted anti-tumor therapy for pancreatic and lung cancer.
HHS Invests $100 Million for Great American Recovery
The U.S. Health and Human Services (HHS) has developed a comprehensive plan to strengthen prevention, expand treatment and carry out the the Great American Recovery.
$1.6 Million Grant Awarded for Hepatitis B Vaccine Research
The Centers for Disease Control and Prevention (CDC) has awarded an unsolicited $1.6 million grant for vaccine research to Danish researchers whose studies have been challenged by mainstream scientists but championed by anti-vaccine activists
$2.7 Million Grant Awarded for NSCLC Research
Trethera Corp. has been awarded a new $2.7 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).
Study Shows Nasal Spray Protects Against Any Flu Strain
The antibody CR9114 shows promise in combating future flu pandemics as it appears to neutralize any influenza virus.
FDA Approves Merck’s KEYTRUDA QLEX for Solid Tumor Indications
The U.S. Food and Drug Administration has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA (pembrolizumab).